A New Application of Amiloride in the Treatment of Patient With Chronic Kidney Disease In Reducing Urinary PROtein
Status:
Completed
Trial end date:
2020-08-01
Target enrollment:
Participant gender:
Summary
Nowadays, the prevalence of chronic kidney disease (CKD) in China is about 10.8%,and nearly
120 million people suffer from CKD, which has become a serious public health problem in
China. Study confirmed that proteinuria is an independent risk factor for the continuous
deterioration of glomerular filtration rate (GFR) in patients with CKD. So it is of great
significance to explore the strategy of reducing proteinuria.
According to our previous study, Amiloride can inhibit the expression of uPAR in podocytes
and reduce proteinuria, This clinical trial aims to evaluate the effect and safety of
Amiloride in decreasing proteinuria for patients with Chronic Kidney Disease.
Phase:
Phase 4
Details
Lead Sponsor:
Guangdong General Hospital Guangdong Provincial People's Hospital